Smith Pharma
0507.639.996 · rovalta.com · 22/09/2026
ACTIVE
Smith Pharma
Financial year 2024 · closed on 31/12/2024
Net result
45,3 k €
+306.1% YoY
Gross margin
153,2 k €
+48.9% YoY
Equity
146,3 k €
+44.9% YoY
Workforce
0,6 ETP
-40.0% YoY
Overview
What does Smith Pharma do?
Smith Pharma is a Private limited company incorporated in 2014. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Willebroek. It employs on average 0,6 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0507.639.996
Incorporation
19/12/2014
Legal form
Private limited company
Registered office
Overwinningsstraat 6
2830 Willebroek · FlandreSee on map
2830 Willebroek · FlandreSee on map
Contributed capital
18 550,00 €
Latest accounts
31/12/2024
Average workforce
0,6 ETP
Activities (NACE)
47730Dispensing chemist in specialised stores· main47730Dispensing chemist in specialised stores47740Retail sale of medical and orthopaedic goods in specialised stores47741Retail sale of medical and orthopaedic goods in specialised stores47750Retail sale of cosmetic and toilet articles in specialised stores47750Retail sale of cosmetic and toilet articles in specialised stores
Joint committees (1)
- 313
Signals
ProfitableGood liquidityPositive cashflowPositive EBITDA
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 9 financial years
| 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||
| Gross margin | 153,2 k € | +48.9% | 102,8 k € | -3.7% | 106,8 k € | -15.7% | 126,7 k € | -37.5% | 202,6 k € | +32.1% | 153,3 k € | +27.6% | 120,1 k € | -35.3% | 185,7 k € | -13.3% | 214,2 k € |
| EBITDA | 133,8 k € | +170% | 49,6 k € | -33.4% | 74,5 k € | +41.7% | 52,5 k € | -53.4% | 112,7 k € | +23.9% | 90,9 k € | +63.0% | 55,8 k € | -59.1% | 136,4 k € | -13.0% | 156,9 k € |
| Operating result | 73,8 k € | +863% | -9,7 k € | -142% | 22,8 k € | +42.1% | 16 k € | -75.2% | 64,6 k € | +50.8% | 42,8 k € | +184% | 15,1 k € | -84.3% | 96 k € | -18.0% | 117 k € |
| Net result | 45,3 k € | +306% | -22 k € | -457% | 6,2 k € | +2013% | -322,3 € | -102% | 20,4 k € | +3499% | -599,8 € | +97.1% | -20,5 k € | -130% | 68,4 k € | +10.3% | 62 k € |
| Balance sheet | |||||||||||||||||
| Equity | 146,3 k € | +44.9% | 101 k € | -17.9% | 123 k € | +5.3% | 116,8 k € | +52.4% | 76,6 k € | +36.3% | 56,2 k € | -1.1% | 56,8 k € | -26.6% | 77,4 k € | -3.9% | 80,5 k € |
| Total assets | 624,1 k € | -0.8% | 629 k € | -9.9% | 698,5 k € | +3.0% | 677,9 k € | -7.5% | 732,7 k € | -1.6% | 744,4 k € | +12.8% | 660 k € | +10.7% | 596,2 k € | +4.9% | 568,2 k € |
| Cash | 56 k € | +61.9% | 34,6 k € | +8.5% | 31,9 k € | -20.8% | 40,2 k € | -90.7% | 433,3 k € | +8.1% | 400,9 k € | +21.0% | 331,3 k € | +44.1% | 230 k € | +45.0% | 158,6 k € |
| Debts | 470,9 k € | -10.8% | 528 k € | -7.6% | 571,7 k € | +2.6% | 557,3 k € | -12.4% | 636,4 k € | -5.4% | 672,5 k € | +13.4% | 592,9 k € | +15.5% | 513,5 k € | +6.6% | 481,8 k € |
| Other | |||||||||||||||||
| Workforce | 0,6 ETP | -40.0% | 1,0 ETP | +66.7% | 0,6 ETP | -45.5% | 1,1 ETP | -21.4% | 1,4 ETP | 0.0% | 1,4 ETP | 0.0% | 1,4 ETP | +16.7% | 1,2 ETP | -14.3% | 1,4 ETP |
Estimate
Indicative valuation
As an indication, this company is worth
between 250 k€ and 500 k€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2024 · 1 active · 2 ended
Active mandates
Active
Ended mandates
Skin Pharma BV
EndedNathalie Vanderhasselt
EndedAt this address
Other companies at this address
| Company | CBE no. |
|---|---|
SKIN PHARMA● Active | 0766.984.146 |
Financials
Annual accounts
Full financial information
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 01/07/2025 | 02/07/2024 | 30/06/2023 | 20/07/2022 | 30/08/2021 | 28/08/2020 |
| General meeting | 30/06/2025 | 24/06/2024 | 26/06/2023 | 27/06/2022 | 23/04/2021 | 07/08/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
10 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 30/06/2025 | 01/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 24/06/2024 | 02/07/2024 | Dutch | |
| Abridged model | 31/12/2022 | 26/06/2023 | 30/06/2023 | Dutch | |
| Abridged model | 31/12/2021 | 27/06/2022 | 20/07/2022 | Dutch | |
| Abridged model | 31/12/2020 | 23/04/2021 | 30/08/2021 | Dutch | |
| Abridged model | 31/12/2019 | 07/08/2020 | 28/08/2020 | Dutch | |
| Abridged model | 31/12/2018 | 24/06/2019 | 27/08/2019 | Dutch | |
| Abridged model | 31/12/2017 | 25/06/2018 | 27/08/2018 | Dutch | |
| Abridged model | 31/12/2016 | 26/06/2017 | 30/08/2017 | Dutch | |
| Abridged model | 31/12/2015 | 27/06/2016 | 29/08/2016 | Dutch |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 250 k€ and 500 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2024 · 1 active · 2 ended
Active mandates
Active
Ended mandates
Skin Pharma BV
EndedNathalie Vanderhasselt
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202445,3 k €↑
- 2023Annual accounts 2023-22 k €↓
- 2023Name changeSmith Pharma
- 2022Annual accounts 20226,2 k €↑
- 2021Annual accounts 2021-322,3 €↓
- 2019Annual accounts 201920,4 k €↑
- 2018Annual accounts 2018-599,8 €↑
- 2017Annual accounts 2017-20,5 k €↓
- 2016Annual accounts 201668,4 k €↑
- 2015Annual accounts 201562 k €
- 2015Name changeVanderhasselt-Pharma
- 19/12/2014IncorporationPrivate limited company